GREENBRAE, Calif.–(BUSINESS WIRE)–Jan 8, 2025–
MarinHealth Medical Center ( MHMC ) announced today that its surgeons have performed the first Aquablation procedures to treat benign prostatic hyperplasia (BPH). MarinHealth is among the few medical centers in the country that have obtained the most advanced version of this AI-enabled, minimally-invasive robotic technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108826689/en/
The Aquablation HYDROS robotic system used by surgeons at MarinHealth Medical Center (MHMC) to perform the first Aquablation procedures to treat benign prostatic hyperplasia (BPH). MarinHealth is among the few medical centers in the country that have obtained the most advanced version of this AI-enabled, minimally invasive robotic technology. (Photo: Business Wire)
Aquablation combines high-definition ultrasound imaging and a precise high-pressure water jet controlled by AI-powered robotic technology to precisely remove prostate tissue. The procedure enables the urologist to tailor the treatment to the patient’s specific anatomy, achieving optimal, durable surgical outcomes similar to those of more invasive procedures. Aquablation has been performed effectively and safely for men with prostate volumes too large for other minimally invasive procedures. In trials involving thousands of men with BPH symptoms, Aquablation has been shown to preserve all aspects of sexual function more effectively than previous technologies.